Submitted by njb2003 on May 30, 2019 - 12:35pm
| Title | Biology and evolution of poorly differentiated neuroendocrine tumors. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Rickman DS, Beltran H, Demichelis F, Rubin MA |
| Journal | Nat Med |
| Volume | 23 |
| Issue | 6 |
| Pagination | 1-10 |
| Date Published | 2017 Jun 06 |
| ISSN | 1546-170X |
| Keywords | Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Azepines, Benzodiazepines, Carcinogenesis, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Cell Differentiation, Cell Lineage, Cell Plasticity, Colonic Neoplasms, Disease Progression, Epigenesis, Genetic, Esophageal Neoplasms, Female, Head and Neck Neoplasms, Humans, Lung Neoplasms, Male, Molecular Targeted Therapy, Neoplasms, Glandular and Epithelial, Neuroendocrine Tumors, Ovarian Neoplasms, Prostatic Neoplasms, Proto-Oncogene Proteins c-met, Proto-Oncogene Proteins c-myc, Pyrimidines, Retinoblastoma Binding Proteins, Triazoles, Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms |
| Abstract | Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on advances in our understanding of the tumorigenesis and treatment of poorly differentiated neuroendocrine tumors. Recent evidence from sequencing indicates that, although neuroendocrine tumors can arise de novo, they can also develop as a result of lineage plasticity in response to pressure from targeted therapies. We discuss the shared genomic alterations of these tumors independently of their site of origin, and we explore potential therapeutic strategies on the basis of recent biological findings. |
| DOI | 10.1038/nm.4341 |
| Alternate Journal | Nat. Med. |
| PubMed ID | 28586335 |